Organon shares jump as Merck’s new women’s health spinoff posts strong start for biosims, infertility drugsnews2021-08-13T15:34:36+00:00August 13th, 2021|Fierce Pharma|
Biosimilars versus biologics: Is marketing madness on the way as biosimilar approvals balloon?news2021-08-13T15:32:39+00:00August 13th, 2021|Fierce Pharma|
Jazz’s Xywav scores the first FDA nod in idiopathic hypersomnia, and big sales could follownews2021-08-13T15:15:48+00:00August 13th, 2021|Fierce Pharma|
FDA denies Rigel’s COVID-19 hopeful Tavalisse for hospitalized patients, asks for late-stage datanews2021-08-13T14:01:07+00:00August 13th, 2021|Fierce Pharma|
Fierce Pharma Asia—Seagen’s $2.6B bet on China biotech; Enhertu’s win over Kadcyla; Takeda’s R&D lessonsnews2021-08-13T10:15:53+00:00August 13th, 2021|Fierce Pharma|
Despite pharma’s pandemic push, consumer trust in the industry still comes down to costs: studynews2021-08-12T20:26:27+00:00August 12th, 2021|Fierce Pharma|
German CDMO Rentschler expands its US presence with Boston biologics sitenews2021-08-12T19:47:44+00:00August 12th, 2021|Fierce Pharma|
J&J, Amgen and Roche face growing biosimilar competition that is driving down prices: reportnews2021-08-12T17:57:41+00:00August 12th, 2021|Fierce Pharma|
Viatris in talks with West Virginia University on plan that could keep idled Morgantown factory afloatnews2021-08-12T17:25:35+00:00August 12th, 2021|Fierce Pharma|
Pfizer halted Chantix distribution then recalled a dozen batches. Now, a generic’s here to help fill the shortagenews2021-08-12T14:45:01+00:00August 12th, 2021|Fierce Pharma|
